Approximately 268 000 Fidelis leads were implanted until distribution was suspended because of a high rate of early failure. Careful analyses of predictors of increased lead-failure hazard are required to help direct future lead design and also to inform decision making on lead replacement. We sought to perform a comprehensive analysis of all potential predictors in a multicenter study. Lead failure rates at 3, 4, and 5 years lead were 5.3%, 10.6%, and 16.8%, respectively. We found that the rate of lead failure continues to accelerate with time. There were 4 independent predictors of higher hazard of failure; center, female gender, noncephalic access vein, and previous lead failure. The major clinical implication of our study relates to management of nonfailed leads at the time of elective pulse generator change. If the failure rate plateaus at the year 5 rate of 6.2%, then over the subsequent 5 years the risk of failure can be estimated to be 23.7%. However, if the failure rate continues to accelerate then the 5-year risk of failure is likely much higher. This suggests that Fidelis replacement should be strongly considered in most patients at the time of generator replacement. Many other factors have to be considered in decision making, including the number of ipsilateral leads, the remaining vascular access, patient age, comorbidities, and life expectancy. If the ipsilateral vein is patent, then the addition of a new lead without extraction is reasonable. If extraction is indicated, then this should be performed at experienced centers. See p 1217. The transitional zone is related to the direction of the QRS axis in the horizontal plane. Although clockwise rotation and counterclockwise rotation are distinct findings on ECG, their clinical values have not been well studied, and their prognostic significance has been studied rarely. In this study, we assessed the independent prognostic values of clockwise rotation and counterclockwise rotation for mortality due to cardiovascular disease and its subtypes in a large cohort of participants obtained from randomly selected health districts in Japan. We found a significant positive association of clockwise rotation and a significant inverse association of counterclockwise rotation with cardiovascular disease mortality in men and in men and women combined, independent of confounding factors including other ECG changes. Although the mechanisms for these associations are not clear at present, in clinical practice, we may need to pay attention to these ECG changes that have been ignored for more than a century. See p 1226.
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Regulatory Role of Dendritic Cells in Postinfarction Healing and Left Ventricular Remodeling
Left ventricular (LV) remodeling after myocardial infarction is a process of complex architectural myocardial alteration and is associated with a poor clinical outcome. Congestive heart failure due to postinfarction LV remodeling remains an open question for clinicians throughout the world, in spite of recent aggressive revascularization and pharmacological therapy in clinical practice. Inflammation and immune responses are integral components of the host reaction to myocardial injury and play a pivotal role in infarct healing and subsequent LV dysfunction. The dendritic cell (DC) is like a maestro conducting various types of inflammatory cells in innate and adoptive immunity. We found that temporal and spatial characteristics of heart-infiltrating DCs and conditional depletion of DCs resulted in adverse infarct expansion and LV dysfunction. This was accompanied by a sustained enhanced inflammatory response and extracellular matrix degradation and suppressed myocardial neoangiogenesis. This impaired tissue repair was associated with augmented infiltration of inflammatory 
Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV)
Among drug-eluting stents released to date, the sirolimus-eluting stent has demonstrated the least amount of late lumen loss, but its efficacy and safety have not been compared head-to-head with the next-generation everolimus-eluting stent. The Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV) trial compared the everolimus-eluting stent with the sirolimus-eluting stent in patients with coronary artery disease. The primary end point was a composite of safety (cardiac death, myocardial infarction, definite stent thrombosis) and efficacy (target vessel revascularization) parameters. A total of 1390 patients were assigned to receive the everolimus-eluting stent and 1384 patients to the sirolimus-eluting stent. At the 9-month follow-up, 4.9% of the patients treated with the everolimus-eluting stent compared with 5.2% of the patients treated with the sirolimus-eluting stent experienced the primary end point (P for noninferiorityϭ0.01). At the 18-month follow-up, this difference remained. The rate of definite stent thrombosis was higher in the sirolimus-eluting group compared with the everolimus-eluting group (0.9% versus 0.2%). The everolimus-eluting stent was found to be noninferior to the sirolimus-eluting stent. See p 1246.
Ischemic Conditioning Protects the Uremic Heart in a Rodent Model of Myocardial Infarction
Ischemic conditioning encompasses a number of established experimental techniques that provide powerful protection for an organ or vascular bed against ischemia/reperfusion injury. However, by and large, clinical trials have not delivered on the promise of preclinical studies undertaken in animals. A number of comorbid conditions such as diabetes mellitus and dyslipidemia have been demonstrated in animal models to attenuate the efficacy of ischemic conditioning. Up to one third of patients presenting with an acute coronary syndrome have chronic kidney disease. These patients have a particularly poor prognosis after acute myocardial infarction that has not been improved by enhanced reperfusion rates. Moreover, patients with chronic kidney disease are frequently excluded from clinical trials. The present study demonstrates that renal dysfunction per se is not a barrier to achieving substantial myocardial protection with ischemic preconditioning, remote ischemic preconditioning, and ischemic postconditioning. The survival pathways thought to be important in transducing the protective effect of ischemic preconditioning, remote ischemic preconditioning, and ischemic postconditioning appear to be preserved and activated to the same degree in 2 different models of experimental renal failure. This study provides the preclinical data to justify the inclusion of patients with chronic kidney disease in future clinical trials of ischemic conditioning as adjuvant therapy to reperfusion in the setting of acute myocardial infarction. See p 1256.
Epoxyeicosatrienoic Acids Contribute With Altered Nitric Oxide and Endothelin-1 Pathways to Conduit Artery Endothelial Dysfunction in Essential Hypertension
Patients with essential hypertension are at increased cardiovascular risk even when their blood pressure levels are well controlled, and restoration of the endothelial function of conduit arteries has emerged as a therapeutic target that may help to prevent the development of cardiovascular complications. In the present study, we demonstrated that several mechanisms contribute to conduit artery endothelial dysfunction in hypertensive patients. In addition to nitric oxide/reactive oxygen species imbalance and alteration in the endothelin-1 pathway, a decrease in epoxyeicosatrienoic acid availability is involved. This is particularly important because epoxyeicosatrienoic acids are not only endothelium-derived relaxing factors, but they also play a major role in maintaining cardiovascular homeostasis by contributing to the regulation of vascular inflammation, cell proliferation, angiogenesis, and hemostasis. Consequently, a new class of pharmacological agents referred to as soluble epoxide hydrolase inhibitors is under development. Therefore, to increase epoxyeicosatrienoic acid availability by reducing their degradation may be particularly useful during essential hypertension. Thus, in addition to decreasing blood pressure, epoxyeicosatrienoic acids could restore the protective action of the endothelium in conduit arteries and prevent the development of atherosclerosis and cardiovascular complications. See p 1266.
